Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 7/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 5/20 | 0.31 |
| ▸ | KCNAB1 | Q14722 | 5/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161524 | 0.92 | PTGER3 (0.37) | P2RY12PTGER3KCNA1KCNAB1 | |
| SCHEMBL12160790 | 0.88 | P2RY12 (0.43) | P2RY12PTGER3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9922425 | 0.88 | BRD4 (0.37) | P2RY12MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL17715368 | 0.85 | GAA (0.37) | P2RY12PTGER3MEN1GAAKMT2A | |
| SCHEMBL9922197 | 0.79 | PTGER3 (0.44) | P2RY12PTGER3KCNA1KCNAB1 | |
| SCHEMBL9923238 | 0.79 | PTGER3 (0.35) | P2RY12PTGER3MEN1KMT2AFBP1 | |
| SCHEMBL9922482 | 0.79 | P2RY12 (0.39) | P2RY12MEN1KMT2ASMN1; SMN2FBP1 | |
| SCHEMBL9922481 | 0.78 | FBP1 (0.40) | P2RY12MEN1KMT2AFBP1 | |
| SCHEMBL9922376 | 0.78 | P2RY12 (0.42) | P2RY12PTGER3MEN1GAAKMT2A | |
| SCHEMBL9922375 | 0.77 | PTGER3 (0.40) | P2RY12PTGER3MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885PTGER3 97/4885MEN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.